# Table of Contents

## From the Editor

**COVID-19: An unwelcome guest that won’t leave**

Long-lasting economic and societal effects, and lingering post-infection symptoms.

Brian F. Mandell, MD, PhD

## The Clinical Picture

**Koebner phenomenon from insulin injection**

Repeated insulin injections in the abdomen led to large red scaly plaques.

Parvathy Madhavan, MBBS; Lauren Hamann, RN, BSN, CDE; Kamal Shoukri, MD; Latha Dulipsingh, MD, FACP, FACE

**Fibrous epulis: A tumorlike gingival lesion**

A 40-year-old woman presented with an enlarging mass measuring 20 mm by 18 mm.

Keiichi Ohta, DDS; Hitoshi Yoshimura, DDS, PhD

## COVID-19 Curbside Consults

**Post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’**

An estimated 10% of COVID-19 survivors continue to experience symptoms weeks to months after symptoms appear.

Susan Vehar, MD; Marina Boushra, MD; Prince Ntiamoah, MD; Michelle Biehl, MD, MS

## Commentary

**What is causing the ‘long-hauler’ phenomenon after COVID-19?**

We are still early in our understanding of COVID-19 and its many manifestations.

Leonard H. Sigal, MD, FACP, FACR, MACR

## Review

**Vaccinating the unvaccinated adult**

Numbers of unvaccinated children are on the rise, but when they grow up, some of them come in for care.

Dillon Cason, MD; Paul Williams, MD, FACP

**Quetiapine for primary insomnia: Consider the risks**

Its cardiometabolic effects and potential for abuse warrant caution in off-label use.

Vania Modesto-Lowe, MD, MPH; Agata K. Harabasz, MD; Sophia A. Walker, MD

CONTINUED ON PAGE 252
CONTINUED FROM PAGE 250

REVIEW.............................................................................................................................................

CABG: When, why, and how? 295
The surgery has developed beyond a “cookie-cutter” generic cardiac operation.
George Dimeling, MD; Laurice Bakaeen, PharmD; Jaikirshan Khatri, MD; Faisal G. Bakaeen, MD, FACS

LETTERS TO THE EDITOR..................................................................................................................

Prostate cancer screening (To the Editor) 260
The costs of PSA testing—both financial and to the patient’s well-being—are not worth it.
Sherry Zhang, MD; Ian Jenkins, MD

LETTERS TO THE EDITOR..................................................................................................................

Prostate cancer screening (To the Editor) 260
Screening should be advised only if benefits clearly outweigh the risks
Kevin Kurator, BS, BA; Ian Jenkins, MD

LETTERS TO THE EDITOR..................................................................................................................

Prostate cancer screening (In Reply) 261
Detection does not lead to overtreatment.
Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU

LETTERS TO THE EDITOR..................................................................................................................

Prostate cancer screening (In Reply) 262
The debate about screening remains fraught, and passions run high on both sides.
Timothy Gilligan, MD

DEPARTMENTS......................................................................................................................................

CME Calendar 256
Correction 294

CME/MOC Instructions 304

Upcoming Features

■ Asthma management: The GINA report

■ Point-of-care ultrasonography

■ Bulimia nervosa: Medical complications